Overview of malignant disorders derived from the histiocytic and dendritic cells

1. Pileri SA, Jaffe R, Facchetti F, Jones DM, Jaffe ES. Histiocytic and dendritic cell neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al. WHO classification of the tumours of haematopoietic and lymphoid dissue. Revised 4th edition Lyon, International Agency for Research on Cancer 2017:465–482.

2. Emile JF, Abla O, Fraitag S, et al. Histiocyte Society. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016;127(22):2672–2681.

3. Vaiselbuh SR, Bryceson YT, Allen CE, et al. Updates on histiocytic disorders. Pediatr Blood Cancer 2014;61(7):1329–1335.

4. Chen M, Ding C, Lu T, et al. Langerhans cell histiocytosis and Erdheim--Chester disease overlap syndrome with bone marrow involvement and type 2 diabetes mellitus. Ann Hematol 2018;97(1):189–192.

5. Novosad O, Skrypets T, Pastushenko Y, et al. MAPK/ERK signal pathway alterations in patients with Langerhans cell histiocytosis. Klin Onkol 2018;31(2):130–136.

6. Diamond EL, Subbiah V, Lockhart AC, et al. Vemurafenib for BRAF V600-Mutant Erdheim-Chester disease and Langerhans cell histiocytosis: Analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol 2018;4(3):384–388.

7. Girschikofsky M, Arico M, Castillo D, et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis 2013;8:72.

8. Haupt R, Minkov M, Astigarraga I, et al. Euro Histio Network. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer 2013;60(2):175–184.

9. Kolenová A, Bubanská E, Špotová A, et al. Cielená liečba závažnej multisystémovej histiocytózy z Langerhansových buniek. Pediatr Prax 2018;19(1):27–31.

10. Nakamine H, Yamakawa M, Yoshino T, et al. Langerhans cell histiocytosis and Langerhans cell sarcoma: current understanding and differential diagnosis. J Clin Exp Hematop 2016;56(2):109–118.

11. Xu XL, Bu WB, Zong WK, Sun JF. Indeterminate cell histiocytosis: a case series and review of the literature. Eur J Dermatol 2017;27(5):559–561.

12. Rezk SA, Spagnolo DV, Brynes RK, et al. Indeterminate cell tumor: a rare dendritic neoplasm. Am J Surg Pathol 2008;32(12):1868–1876.

13. Adam Z, Ježová M, Šlampa P, et al. Histiocytóza z indeterminovaných buněk – vymizení kožní infiltrace po ozáření elektronovým svazkem a aplikace 2-chlorodeoxyadenozinu: kazuistika. Vnitř Lék 2017;63(4):284–288.

14. Cohen-Aubart F, Emile JF, Carrat F, et al. Phenotypes and survival in Erdheim-Chester disease: Results from a 165-patient cohort. Am J Hematol; publikováno elektronicky 2. února 2018; DOI: 10.1002/ajh.25055.

15. Suzuki H, Wanibuchi M, Komatsu K, et al. Erdheim-Chester disease involving the central nervous system with the unique appearance of a coated vertebral artery. NMC Case Rep J 2016;3(4):125–128.

16. Papo M, Diamond EL, Cohen-Aubart F, et al. High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. Blood 2017;130(8):1007–1013.

17. Goyal G, Shah MV, Call TG, Litzow MR, et al. Efficacy of biological agents in the treatment of Erdheim-Chester disease. Br J Haematol; publikováno elektronicky 30. října 2017; DOI:10.1111/bjh.14997.

18. Cohen Aubart F, Emile JF, et al. Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). Blood 2017;130(11):1377–1380.

19. Adam Z, Petrášová H, Řehák Z, et al. Hodnocení pěti let léčby Erdheimovy-Chesterovy nemoci anakinrou. Vnitř Lék 2016;62(10): 820–832.

20. Adam Z, Řehák Z, Koukalová R, et al. PET-CT dokumentovaná kompletní remise Erdheimovy-Chesterovy nemoci, trvající více než 4 roky od zahájení léčby kladribinem. Vnitř Lék 2014;60(5-6):501–511.

21. Szturz P, Adam Z, Řehák Z, et al. Xanthelasma palpebrarum responding to interleukin-1 blockade. Intern Med J 2014;44(6):617–618.

22. Adam Z, Szturz P, Pour L, et al. Kladribin je vysoce účinný v léčbě histiocytózy z Langerhanosových buněk a vzácných chorob ze skupiny juvelního xantogranulomu. Vnitř Lék 2012;58(6):455–465.

23. Luder CM, Nordmann TM, et al. Histiocytosis – cutaneous manifestations of hematopoietic neoplasm and non-neoplastic histiocytic proliferations. J Eur Acad Dermatol Venereol; publikováno elektronicky 16. ledna 2018; DOI: 10.1111/jdv.14794.

24. Mahendran P, Wee J, Chong H, Natkunarajah J. Necrobiotic xanthogranuloma treated with lenalidomide. Clin Exp Dermatol 2018;43(3):345–347.

25. Sagiv O, Thakar SD, Morrell G, et al. Rituximab monotherapy is effective in treating orbital necrobiotic xanthogranuloma. Ophthal Plast Reconstr Surg 2018;34(1):e24–e27.

26. Techavichit P, Sosothikul D, Chaichana T, et al. BRAF V600E mutation in pediatric intracranial and cranial juvenile xanthogranuloma. Hum Pathol 2017;69:118–122.

27. Fölster-Holst R. Severe systemic juvenile xanthogranuloma is an indication for systemic therapy. Br J Dermatol 2017;176(2):302–304.

28. Wruhs M, Feldmann R, Sawetz I, et al. Necrobiotic xanthogranuloma in a patient with multiple myeloma. Case Rep Dermatol 2016;8(3):350–353.

29. Kusumgar P, Vijaya PH, Monappa V. Adult-onset asthma and periocular xanthogranuloma: A rare case report. Can J Ophthalmol 2016;51(6):e168–e171.

30. Klingner M, Hansel G, Schönlebe J, et al. Disseminated necrobiotic xanthogranuloma. Hautarzt 2016;67(11):902–906.

31. Honda Y, Nakamizo S, Dainichi T, et al. Adult-onset asthma and periocular xanthogranuloma associated with IgG4-related disease with infiltration of regulatory T cells. J Eur Acad Dermatol Venereol 2017;31(2):e124–e125.

32. Miguel D, Lukacs J, Illing T, et al. Treatment of necrobiotic xanthogranuloma - a systematic review. J Eur Acad Dermatol Venereol 2017;31(2):221–235.

33. Maintz L, Wenzel J, Irnich M, et al. Successful treatment of systemic juvenile xanthogranulomatosis with cytarabine and 2-chlorodeoxyadenosine: case report and review of the literature. Br J Dermatol 2017;176(2):481–487.

34. Higgins LS, Go RS, Dingli D, et al. Clinical features and treatment outcomes of patients with necrobiotic xanthogranuloma associated with monoclonal gammopathies. Clin Lymphoma Myeloma Leuk 2016;16(8):447–452.

35. Adam Z, Veselý K, Motyčková I, et al. Oční víčka se žlutými granulomy a kašel. Periokulární xanthogranulom asociovaný s adult-onset astmatem. Popis případu a přehled klinických forem juvenilního xantogranulomu. Vnitř Lék 2012;58(5):365–377.

36. Adam Z, Zahradová L, Krejčí M, et al. Difúzní ploché normolipemické xanthomatomy a nekrobiotický xantogranulom asociovaný s monoklonální gamapatií. Vnitř Lék 2010;56(11):1158–1168.

37. Ranganathan S. Histiocytic proliferations. Semin Diagn Pathol 2016;33(6):396–409.

38. Adam Z, Koukalová R, Řehák Z, Čermák A, Krejčí M, Pour L. Neinfekční nemaligní lymfadenopatie – sinusová histiocytóza s masivní lymfadenopatií, nemoc Rosaiova-Dorfmanova. Transfuze Hematol dnes 2018;24(3):166–173.

39. Huhn D. Therapy of malignant histiocytosis. Haematol Blood Transfus 1981;27:211–216.

40. Kommalapati A, Tella SH, Durkin M, et al. Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes. Blood 2018;131(2):265–268.

41. Jiang M, Bennani NN, Feldman AL. Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms. Expert Rev Hematol 2017;10(3):239–249.

42. Vokuhl C, Oschlies I, Klapper W, et al. Histiocytic diseases in child-hood and adolescence. Pathologe 2015;36(5):443–450.

43. Magro CM, Kazi N, Sisinger AE. Primary cutaneous histiocytic sarcoma: A report of five cases with primary cutaneous involvement and review of the literature. Ann Diagn Pathol 2018;32:56–62.

44. Voruz S, Cairoli A, Naveiras O, et al. Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma. Haematologica 2018;103(1):e39–e41.

45. Iwabuchi H, Kawashima H, Umezu H, et al. Successful treatment of histiocytic sarcoma with cladribine and high-dose cytosine arabinoside in a child. Int J Hematol 2017;106(2):299–303.

46. Létalová E, Moulis M, Klincová M, et al. Histiocytární sarkom. Vnitř Lék 2013;59(12):1117–1122.

47. Chen T, Gopal P. Follicular dendritic cell sarcoma. Arch Pathol Lab Med 2017;141(4):596–599.

48. Facchetti F, Lorenzi L. Follicular dendritic cells and related sarcoma. Semin Diagn Pathol 2016;33(5):262–276.

49. Li J, Zhou ML, Zhou SH. Clinical and pathological features of head and neck follicular dendritic cell sarcoma. Hematology 2015;20(10):571–583.

50. Jain P, Milgrom SA, Patel KP, et al. Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. Br J Haematol 2017;178(3):403–412.

51. Sasaki M, Izumi H, Yokoyama T, et al. Follicular dendritic cell sarcoma treated with a variety of chemotherapy. Hematol Oncol 2017;35(4): 905–908.

52. Purkait S, Mallick S, Joshi PP, et al. Retroperitoneal and mediastinal follicular dendritic cell sarcoma: report of 3 cases with review of literature. Hematol Oncol 2017;35(3):374–379.

53. Ninkovic S, Cole-Sinclair MF. Interdigitating dendritic cell sarcoma: diagnostic pitfalls, treatment challenges and role of transdifferentation in pathogenesis. Pathology 2017;49(6):643–646.

54. Nguyen CM, Cassarino D. Primary cutaneous interdigitating dendritic cell sarcoma: a case report and review of the literature. Am J Dermatopathol 2016;38(8):628–631.

55. Pokuri VK, Merzianu M, Gandhi S, et al. Interdigitating dendritic cell sarcoma. J Natl Compr Canc Netw 2015;13(2):128–132.

56. Di Liso E, Pennelli N, Lodovichetti G, et al. Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature. Cancer Biol Ther 2015;16(8):1128–1135.

57. Adam Z, Pour L, Veselý K, et al. Interdigitating dendritic cell sarcoma of the leg. Onkologie 2009;32(6):364–365.

58. Adam Z, Veselý K, Krejčí M, et al. Interdigitující dendritický sarkom dolní končetiny rezistentní k vysokodávkované chemoterapii BEAM s transplantací autologních hemopoetických kmenových buněk. Vnitř Lék 2009;55(2):147–157.

59. Minoia F, Bovis F, Davì S, et al. Development and initial validation of the macrophage activation syndrome/primary hemophagocytic lymphohistiocytosis score, a diagnostic tool that differentiates primary hemophagocytic lymphohistiocytosis from macrophage activation syndrome. J Pediatr 2017;189:72–78.

60. Janka GE, Lehmberg K. Hemophagocytic syndromes – an update. Blood Rev 2014;28(4):135–142.

61. Lehmberg K, Sprekels B, Nichols KE, et al. Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents. Br J Haematol 2015;170(4):539–549.

62. Ruscitti P, Rago C, Breda L, et al. Macrophage activation syndrome in Still‘s disease: analysis of clinical characteristics and survival in paediatric and adult patients. Clin Rheumatol 2017;36(12):2839–2845.

63. Grom AA. Primary hemophagocytic lymphohistiocytosis and macrophage activation syndrome: the importance of timely clinical differentiation. J Pediatr 2017;189:19–21.

64. Otrock ZK, Daver N, Kantarjian HM, Eby CS. Diagnostic challenges of hemophagocytic lymphohistiocytosis. Clin Lymphoma Myeloma Leuk 2017;17S:S105–S110.

65. Ammann S, Lehmberg K, Zur Stadt U, et al. Effective immunological guidance of genetic analysesi exome sequencing in patients evaluated for hemophagocytic lymphohistiocytosis. J Clin Immunol 2017;37(8):770–780.

66. Al-Samkari H, Berliner N. Hemophagocytic lymphohistiocytosis. Annu Rev Pathol 2018;13:27–49.

67. Henter JI, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48(2):124–131.

68. Saarela M, Senthil K, Jones J, et al. Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab. Neurology 2018;90(18):849–851.

69. Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer 2013;60(1):101–109.

70. Machaczka M, Vaktnäs J, Chiang SC, et al. Alemtuzumab treatment for hemophagocytic lymphohistiocytosis. Nat Rev Clin Oncol 2010;7(10):596.

71. Strout MP, Seropian S, Berliner N. Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis. Nat Rev Clin Oncol 2010;7(7):415–420.

72. Olin RL, Nichols KE, Naghashpour M, et al. Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis. Am J Hematol 2008;83(9):747–749.

73. Makay B, Yilmaz S, Türkyilmaz Z, et al. Etanercept for therapy-resistant macrophage activation syndrome. Pediatr Blood Cancer 2008;50(2):419– 421.

74. Takahashi N, Naniwa T, Banno S. Successful use of etanercept in the treatment of acute lupus hemophagocytic syndrome. Mod Rheumatol 2008;18(1):72–75.

75. Kikuchi H, Yamamoto T, Asako K, et al. Etanercept for the treatment of intractable hemophagocytic syndrome with systemic lupus erythematosus. Mod Rheumatol 2012;22(2):308–311.

76. Ramanan AV, Schneider R. Macrophage activation syndrome fol-lowing initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol 2003;30(2):401–403.

77. Divithotawela C, Garrett P, Westall G, et al. Successful treatment of cytomegalovirus associated hemophagocytic lymphohistiocytosis with the interleukin 1 inhibitor – anakinra. Respirol Case Rep 2015;4(1):4–6.

78. Ježová M, Gaillyová R. Familiární hemofagocytující lymfohistiocytóza: od autopsie k prenatální diagnóze. Kazuistika. Cesk Patol 2017;53(1):29–34.

79. Wang H, Xiong L, Tang W, Zhou Y, Li F. A systematic review of malignancy-associated hemophagocytic lymphohistiocytosis that needs more attentions. Oncotarget 2017;8(35):59977–59985.

80. Daver N, McClain K, Allen CE, et al. A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer 2017;123(17):3229–3240.

81. Šrámek J, Karvunidis T, Lysák D, Harazim M, Karas M, Jindra P. Hemofagocytární lymfohistiocytóza u dospělých – review a kazuistika. Vnitřní Lék 2018;64(3):300–307.

82. Saevels K, Robert D, Van den Broeck S, et al. EBV-associated hemophagocytic lymphohistiocytosis complicated by severe coagulation disorders and opportunistic infections: case report of a survivor. Clin Case Rep 2017;6(1):115–118.

83. Bergsten E, Horne A, Aricó M, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood 2017;130(25):2728–2738.

84. Zandvakili I, Conboy CB, Ayed AO, et al. Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A second experience. Am J Hematol; publikováno elektronicky 8. února 2018; DOI: 10.1002/ajh.25063.

85. Broglie L, Pommert L, Rao S, et al. Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis. Blood Adv 2017;1(19):1533–1536.

86. Lorenz F, Klimkowska M, Pawłowicz E, et al. Clinical characteristics, therapy response, and outcome of 51 adult patients with hematological malignancy-associated hemophagocytic lymphohistiocytosis: a single institution experience. Leuk Lymphoma 2018;3:1–11.

87. Pepe F, Disma S, Teodoro C, et al. Kikuchi-Fujimoto disease: a clinicopathologic update. Pathologica 2016;108(3):120–129.

88. Mathew LM, Kapila R, Schwartz RA. Kikuchi-Fujimoto disease: a diagnostic dilemma. Int J Dermatol 2016;55(10):1069–1075.

89. Cuglievan B, Miranda RN. Kikuchi-Fujimoto disease. Blood 2017;129(7):917–918.

90. Szturz P, Adam Z, Chovancová J, et al. Cytokine analysis in a patient with relapsing Kikuchi-Fujimoto disease. Leuk Lymphoma 2012;53(4):743–745.